EyePoint, Inc (EYPT)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.14

+0.13 (+4.32%)

Market Cap: $257.39M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

51%(20/39)

Avg Surprise

-21.71%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.92

Range$-1.09 - $-0.60

10 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.81-12.8%

60d ago$-0.93+1.0%

30d ago$-0.91-1.3%

7d ago$-0.91-1.3%

Current$-0.92

Revenue Consensus

$252500

Range$0 - $600000

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.96

Range$-1.69 - $-0.02

11 analysts

Revenue Consensus

$702150

Range$-277620 - $2M

13 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.96	$-1.69 - $-0.02	-	-	11	-	-
Sep 30, 2026Sep 26EST	-	$-0.92	$-1.09 - $-0.60	-	-	10	1 9 30d	-
Jun 30, 2026Jun 26 Reported Aug 5, 2026Reported Aug 5	$-1.09	$-0.92	$-1.20 - $-0.77	-18.48%	Miss	12	0 1 30d	-28.2%
Mar 31, 2026Mar 26 Reported May 6, 2026Reported May 6	$-0.99	$-0.81	$-0.89 - $-0.76	-22.22%	Miss	10	0 4 30d	-52.3%
Dec 31, 2025Dec 25 Reported Mar 4, 2026Reported Mar 4	$-0.81	$-0.75	$-0.90 - $-0.61	-8.33%	Miss	9	1 1 30d	-26.6%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.85	$-0.77	$-0.94 - $-0.67	-10.39%	Miss	10	6 3 30d	-57.4%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-0.85	$-0.80	$-0.96 - $-0.55	-6.25%	Miss	12	1 8 30d	-46.6%
Mar 31, 2025Mar 25 Reported May 7, 2025Reported May 7	$-0.65	$-0.69	$-0.83 - $-0.63	+5.80%	Beat	10	0 6 30d	-18.2%
Dec 31, 2024Dec 24 Reported Mar 5, 2025Reported Mar 5	$-0.64	$-0.48	$-0.64 - $-0.31	-34.31%	Miss	11	3 0 30d	-93.9%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-0.54	$-0.54	$-0.69 - $-0.40	+0.00%	Beat	12	1 0 30d	-63.6%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.58	$-0.51	$-0.66 - $-0.34	-13.73%	Miss	10	No revisions (30d)	+4.9%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-0.55	$-0.42	$-0.63 - $-0.30	-30.95%	Miss	10	1 0 30d	+1.8%
Dec 31, 2023Dec 23 Reported Mar 7, 2024Reported Mar 7	$-0.33	$-0.49	$-0.76 - $-0.29	+32.65%	Beat	11	No revisions (30d)	+71.6%
Sep 30, 2023Sep 23 Reported Nov 1, 2023Reported Nov 1	$-0.33	$-0.51	$-0.70 - $-0.39	+35.29%	Beat	7	No revisions (30d)	+32.7%
Jun 30, 2023Jun 23 Reported Aug 2, 2023Reported Aug 2	$-0.61	$0.37	$-0.72 - $1.52	-264.86%	Miss	8	1 0 30d	-17.3%
Mar 31, 2023Mar 23 Reported May 3, 2023Reported May 3	$-0.56	$-0.65	$-0.75 - $-0.62	+13.85%	Beat	6	No revisions (30d)	-7.7%
Dec 31, 2022Dec 22 Reported Mar 2, 2023Reported Mar 2	$-1.16	$-0.61	$-0.67 - $-0.57	-90.16%	Miss	6	No revisions (30d)	-96.6%
Sep 30, 2022Sep 22 Reported Nov 2, 2022Reported Nov 2	$-0.49	$-0.69	$-0.79 - $-0.63	+28.99%	Beat	5	No revisions (30d)	+15.5%
Jun 30, 2022Jun 22 Reported Aug 3, 2022Reported Aug 3	$-0.52	$-0.55	$-0.59 - $-0.46	+5.45%	Beat	6	No revisions (30d)	-23.8%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-0.52	$-0.59	$-0.64 - $-0.50	+11.86%	Beat	5	No revisions (30d)	-4.0%
Dec 31, 2021Dec 21 Reported Mar 3, 2022Reported Mar 3	$-0.59	$-0.53	$-0.59 - $-0.41	-11.32%	Miss	4	No revisions (30d)	+41.0%
Sep 30, 2021Sep 21 Reported Nov 3, 2021Reported Nov 3	$-0.58	$-0.40	$-0.47 - $-0.36	-45.00%	Miss	5	2 0 30d	-93.3%
Jun 30, 2021Jun 21 Reported Aug 4, 2021Reported Aug 4	$-0.42	$-0.45	$-0.52 - $-0.30	+6.67%	Beat	6	No revisions (30d)	+58.0%
Mar 31, 2021Mar 21 Reported May 5, 2021Reported May 5	$-0.50	$-0.50	$-0.54 - $-0.35	+0.00%	Beat	5	1 0 30d	+54.5%
Dec 31, 2020Dec 20 Reported Mar 4, 2021Reported Mar 4	$-1.00	$-0.17	$-0.81 - $0.46	-488.24%	Miss	5	No revisions (30d)	+0.0%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-0.30	$-0.30	$-0.36 - $-0.28	+0.00%	Beat	4	2 0 30d	+80.0%
Jun 30, 2020Jun 20 Reported Aug 5, 2020Reported Aug 5	$-1.00	$-1.05	$-1.07 - $-1.04	+4.76%	Beat	4	No revisions (30d)	+9.1%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$-1.10	$-0.95	$-0.96 - $-0.93	-15.79%	Miss	4	No revisions (30d)	+31.3%
Dec 31, 2019Dec 19 Reported Mar 5, 2020Reported Mar 5	$-1.00	$-1.17	$-1.19 - $-1.17	+14.53%	Beat	3	1 0 30d	+16.7%
Sep 30, 2019Sep 19 Reported Nov 7, 2019Reported Nov 7	$-1.50	$-1.37	$-1.38 - $-1.35	-9.49%	Miss	4	No revisions (30d)	+21.1%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-1.10	$-1.20	$-1.20 - $-1.20	+8.33%	Beat	2	No revisions (30d)	+41.8%
Mar 31, 2019Mar 19 Reported May 8, 2019Reported May 8	$-1.60	$-1.37	$-1.39 - $-1.32	-16.79%	Miss	3	No revisions (30d)	-56.9%
Dec 31, 2018Dec 18 Reported Mar 14, 2019Reported Mar 14	$-1.20	$-1.40	$-1.41 - $-1.39	+14.29%	Beat	2	No revisions (30d)	+7.7%
Sep 30, 2018Sep 18 Reported Nov 6, 2018Reported Nov 6	$-1.90	$-1.47	$-1.53 - $-1.42	-29.25%	Miss	3	No revisions (30d)	-26.7%
Jun 30, 2018Jun 18 Reported Sep 12, 2018Reported Sep 12	$-1.89	$-1.40	$-1.43 - $-1.37	-35.00%	Miss	3	No revisions (30d)	-18.1%
Mar 31, 2018Mar 18 Reported May 8, 2018Reported May 8	$-1.02	$-1.20	$-1.22 - $-1.18	+15.00%	Beat	4	No revisions (30d)	+32.0%
Dec 31, 2017Dec 17 Reported Feb 7, 2018Reported Feb 7	$-1.30	$-1.50	-	+13.33%	Beat	-	-	-64900.0%
Sep 30, 2017Sep 17 Reported Nov 7, 2017Reported Nov 7	$-1.50	$-1.50	-	+0.00%	Beat	-	-	-
Jun 30, 2017Jun 17 Reported Sep 11, 2017Reported Sep 11	$-1.60	$-1.50	-	-6.67%	Miss	-	-	-
Mar 31, 2017Mar 17 Reported May 4, 2017Reported May 4	$-1.50	$-1.50	-	+0.00%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Feb 7, 2017Reported Feb 7	$-0.00	N/A	-	+99.89%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.84	EV/EBITDA	N/A
Price/FCF	-1.00x	FCF Yield	-99.83%
Profitability
Profit Margin	0.00%	Operating Margin	-19207.00%
ROE	-148.70%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	4.50x	Quick Ratio	4.46x
Trading Statistics
Beta	1.68	Avg Volume	3.31M
52-Week High	$19.11	52-Week Low	$3.05

Technical Indicators Dashboard

Moving Averages

SMA 10$3.23

SMA 20$3.42

SMA 50$5.40

SMA 200$11.88

EMA 10$3.25

EMA 20$3.56

EMA 50$5.44

EMA 200$9.97

MACD

Line: -0.59Signal: -0.73Hist: 0.14

ADX

ADX: 41.1+DI: 15.7-DI: 35.1

Aroon & PSAR

Aroon Up4.0

Aroon Down96.0

PSAR$3.73

Bollinger Bands

Upper Band$4.03

Lower Band$2.81

%B Position3573%(Upper)

Band Width0.27

RSI (14-Day)

Neutral

33.6

Momentum Oscillators

Stoch %K14.9

Stoch %D15.4

Williams %R-68.7

ROC (10d)-2.8%

Momentum-0.09

CCI (20d)-90.4

MFI (14d)40.8

Volatility Measures

ATR (14d)$0.32(10.1%)

StdDev (20d)0.31

Hist Vol66.2%(High)

Volume Flow

VWAP$3.11

OBV-40.0M

AD Line58.9M

CMF (20d)-0.171

Volume Metrics

Avg Vol (20d)3.0M

Vol Ratio0.9x

VWMA (20d)$3.48

Pivot Points

R3$3.19

R2$3.12

R1$3.07

Pivot Point$3.00

S1$2.94

S2$2.87

S3$2.82

Advanced Oscillators

TSI-37.13

Ultimate Osc43.8

KST-271.33

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$507,000	$696,000	$619,000	$966,000	$5.33M	$24.45M	$11.59M	$10.52M	$9.48M	$11.68M	$14.03M	$15.20M
Cost of Revenue	$0	$0	$2.07M	$0	$165,000	$805,000	$-1,495,000	$736,000	$0	$759,000	$-3,634,000	$1.20M
Gross Profit	$507,000	$696,000	$-1,447,000	$966,000	$5.17M	$23.65M	$13.08M	$9.79M	$9.48M	$10.93M	$17.66M	$14.00M

Operating Expenses	$97.89M	$87.92M	$68.90M	$62.99M	$67.39M	$72.48M	$58.32M	$42.54M	$44.02M	$44.25M	$34.02M	$28.40M
R&D	$83.61M	$72.15M	$59.21M	$47.75M	$55.50M	$58.57M	$43.42M	$29.54M	$29.82M	$30.14M	$17.95M	$17.36M
SG&A	$14.24M	$15.24M	$11.38M	$14.49M	$11.86M	$13.88M	$12.54M	$12.97M	$12.75M	$14.10M	$11.25M	$10.56M
Operating Income	$-97,380,000	$-87,226,000	$-70,345,000	$-62,025,000	$-62,227,000	$-48,837,000	$-45,239,000	$-32,748,000	$-34,546,000	$-33,321,000	$-16,354,000	$-14,398,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-94,470,000	$-84,882,000	$-67,423,000	$-59,732,000	$-59,333,000	$-45,195,000	$-41,309,000	$-29,361,000	$-30,826,000	$-29,284,000	$-14,016,000	$-12,612,000
Income Tax Expense	$0	$-50,000	$0	$0	$93,000	$0	$0	$0	$0	$0	$0	$0

Net Income	$-94,470,000	$-84,832,000	$-67,609,000	$-59,732,000	$-59,426,000	$-45,195,000	$-41,399,000	$-29,361,000	$-30,826,000	$-29,284,000	$-14,099,000	$-12,612,000

EBITDA	$-93,970,000	$-85,024,000	$-67,635,000	$-60,107,000	$-59,996,000	$-46,431,000	$-42,638,000	$-30,829,000	$-32,156,000	$-29,556,000	$-14,426,000	$-12,536,000
EBIT	$-94,470,000	$-84,882,000	$-67,390,000	$-59,732,000	$-59,333,000	$-45,195,000	$-41,295,000	$-29,361,000	$-30,826,000	$-29,284,000	$-14,016,000	$-12,612,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about EYPT

News

Here's Why You Should Add EYPT Stock to Your Portfolio Now

EyePoint Pharmaceuticals (EYPT) is a clinical-stage biotechnology company developing treatments for retinal diseases, with its lead candidate, Duravyu...

TradingView•Oct 15, 2026 9:41 AM ET10/15/26•Somewhat-Bullish

EyePoint Pharmaceuticals stock fell 3.08 percent as LUCIA nears

EyePoint Pharmaceuticals (EYPT) stock dropped 3.08% to $3.15 after its DURAVYU drug missed a primary endpoint in the LUGANO trial...

AD HOC NEWS•Oct 6, 2026 4:00 AM ET10/6/26•Bearish

EyePoint Pharmaceuticals stock holds at USD 3.25 after loss

EyePoint Pharmaceuticals (EYPT) closed at USD 3.25 on Nasdaq after reporting a significant drop in second-quarter revenue to USD 507,000...

AD HOC NEWS•Oct 4, 2026 7:25 AM ET10/4/26•Somewhat-Bearish

PV3B Stock Price and Chart — HAN:PV3B

This article provides detailed information on EyePoint, Inc. (PV3B) stock traded on the Hannover Stock Exchange, including key financial stats, upcoming earnings, company info...

TradingView•Sep 29, 2026 2:50 PM ET9/29/26•Bullish

JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

JonesTrading analyst Debanjana Chatterjee has reiterated a Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $20.00. This recommendation comes despite the company reporting a significant GAAP net loss...

The Globe and Mail•Sep 28, 2026 5:57 PM ET9/28/26•Somewhat-Bullish

EYPT Valuation and Fair Value

P/E: -0.8x
Forward P/E: 6.2x
P/FCF: -1.0x
P/B: 1.6x

See GNG's fair value

EYPT Profitability: Margins, ROIC and FCF

Gross margin: 25.9%
Operating margin: -19207.0%
Net margin: 0.0%
ROE: -148.7%
FCF margin: -9730.2%
FCF yield: -99.8%

EYPT Competitors

Company	Ticker
Prelude Therapeutics Inc	PRLD
OraSure Technologies Inc	OSUR
Palisade Bio Inc	PALI
Vanda Pharmaceuticals Inc	VNDA
Standard Biotools Inc	LAB
Inhibikase Therapeutics Inc	IKT
Nautilus Biotechnology Inc	NAUT
Century Therapeutics Inc	IPSC

Sector: Healthcare

EYPT Analyst Ratings

Consensus: Buy
Analysts: 13
Strong Buy: 1
Buy: 6
Hold: 6
Sell: 0
Strong Sell: 0

EYPT Bull Case vs Bear Case

Bear case

EYPT beat EPS estimates in 12.5% of its last 8 reported quarters.
EYPT's quarterly revenue changed -90.5% year over year.

EYPT Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -11.8%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.92
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 9 down

Frequently Asked Questions About EYPT

Does EYPT pay dividends?

EyePoint, Inc (EYPT) does not currently pay a regular dividend.

What is EYPT's market cap?

EyePoint, Inc (EYPT) has a market capitalization of $257.39M with a current stock price of $3.14.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In